drugset / Trial / NCT03822559
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time, once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China as well as comparison of safety.
Timeline
- Start
- 2019-01-20
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tafluprost | Other / unclassified | 0.015 mg/ml | Other |
| Subject | Timolol | Other / unclassified | 5 mg/ml | Other |